封面
市場調查報告書
商品編碼
1271232

診斷用放射性醫藥品和顯影劑市場:各放射性醫藥品,顯影劑(各治療,各用途),各地區 - 規模,佔有率,展望,機會分析,2023年~2030年

Diagnostic Radiopharmaceuticals and Contrast Media Market, By Radiopharmaceuticals (, By Contrast Media ((by Procedure and by Application ), and By Geography - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

出版日期: | 出版商: Coherent Market Insights | 英文 170 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

放射性藥物用於生成器官或組織的圖像,這一過程稱為閃爍顯像。同時,造影劑用於成像技術以增強圖像上身體組織之間的差異。它是一種用於在醫學成像中增加體內結構/流體對比度的物質。

心血管疾病患病率增加、癌症負擔增加、診斷中心數量增加、對圖像引導程序和診斷的需求增加以及對診斷用放射性藥物和造影劑的需求增加,這些都預計是推動全球診斷放射性藥物和造影劑市場成長的主要因素。

本報告對全球診斷用放射性藥物和造影劑市場進行了深入分析,並提供了預測期(2023-2030年)的市場規模(百萬美元)和年複合成長率(CAGR %),以2022年為基數年。

目錄

第1章 調查的目的與前提條件

  • 調查的目的
  • 前提條件
  • 簡稱

第2章 市場展望

  • 報告概要
    • 市場定義和範圍
  • 摘要整理
    • 市場概述:各放射性醫藥品
    • 市場概述:各顯影劑
    • 市場概述:各地區
  • Coherent Opportunity Map(COM)

第3章 市場動態,法律規章,趨勢分析

  • 市場動態
    • 全球心血管疾病和癌症的負擔增加
    • 放射性醫藥品的半衰期很短,有關技術的成本高
    • 各影像誘導治療和診斷的需求增加
  • 影響分析
  • 主要的焦點
  • 法規情境
  • 產品銷售/核准
  • PEST分析
  • PORTER的分析
  • 合併、收購情境

第4章 診斷用放射性醫藥品和顯影劑的全球市場- 冠狀病毒(COVID-19)大流行造成的影響

  • COVID-19流行病學資料
  • 供給側和需求側的分析
  • 經濟影響

第5章 診斷用放射性醫藥品和顯影劑的全球市場,各放射性醫藥品,2017年~2030年

  • 成像模式的各類型
  • 市場規模、預測,YoY成長率,2017年~2030年
  • 市場規模與預測,及Yo-Y成長率,2017-2030年
  • 各用途
  • 市場規模、預測,及Yo-Y成長率,2017-2030年
  • 市場規模與預測,及與前一年同期比較成長率,2017年~2030年

第6章 診斷用放射性醫藥品和顯影劑的全球市場,各顯影劑,2017-2030年

  • 各治療
  • 市場規模、預測,YoY成長率,2017-2030年
  • 市場規模與預測,及Yo-Y成長率,2017-2030年
  • 市場規模與預測,及與前一年同期比較成長率,2017年~2030年
  • 各用途
  • 市場規模、預測,及Yo-Y成長率,2017-2030年
  • 市場規模與預測,及Yo-Y成長率,2017-2030年
  • 市場規模與預測,及與前一年同期比較成長率,2017年~2030年
  • 市場規模與預測,及與前一年同期比較成長率,2017年~2030年
  • 市場規模與預測,及與前一年同期比較成長率,2017年~2030年

第7章 診斷用放射性醫藥品和顯影劑的全球市場,各地區,2017年~2030年

  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東、非洲地區

第8章 競爭情形

  • Siemens Healthineers
  • Nordion Inc.
  • Lantheus Holdings Inc.
  • Guerbet Group
  • GE Healthcare
  • Curium
  • Bracco Imaging SpA
  • Bayer AG
  • NTP Radioisotopes SOC Ltd.
  • Cardinal Health Inc.

第9章 Section

  • 關於調查手法
  • 關於出版社
簡介目錄
Product Code: CMI5666

Radiopharmaceuticals are used to produce images of organs or tissues of interest, a process that is called scintigraphy. While, contrast media is used in imaging techniques to enhance the differences between body tissues on images. It is a substance used to increase the contrast of structures/fluids within the body in medical imaging.

Market Dynamics:

Increase in prevalence of cardiovascular diseases, rise in burden of cancer, increasing number of diagnostic centres, increasing demand for image-guided procedures and diagnostics, and increase in demand for diagnostic radiopharmaceuticals and contrast media, are major factors expected to propel growth of the global diagnostic radiopharmaceuticals and contrast media market.

For instance, in October 2022, Duchem Bio announced the launched of FACBC, the world's first radiopharmaceutical used when diagnosing prostate cancer patients, in Korea. The drug, developed by Nihon Medi Physics, a Japanese pharmaceutical company, is used when conducting positron emission tomography (PET) in patients suspected of having prostate cancer recurrence due to an increase in the prostate-specific antigen (PSA) in the blood after prostate cancer treatment.

Key features of the study:

  • This report provides in-depth analysis of the global diagnostic radiopharmaceuticals and contrast media market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2023-2030), considering 2022 as the base year.
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
  • It profiles key players in the global diagnostic radiopharmaceuticals and contrast media market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
  • Key companies covered as a part of this study include Siemens Healthineers, Nordion Inc., Lantheus Holdings Inc., Guerbet Group, GE Healthcare, Curium, Bracco Imaging SpA, Bayer AG, Cardinal Health Inc., and NTP Radioisotopes SOC Ltd.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
  • The global diagnostic radiopharmaceuticals and contrast media market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global diagnostic radiopharmaceuticals and contrast media market.

Detailed Segmentation:

  • Global Diagnostic Radiopharmaceuticals and Contrast Media Market, By Radiopharmaceuticals
    • By Type of Imaging Modality:
      • SPECT
      • PET
    • By Application
      • Diagnostic application
      • Therapeutic application
  • Global Diagnostic Radiopharmaceuticals and Contrast Media Market, By Contrast Media
    • By Procedure
      • X-Ray/Computed Tomography (CT)
      • Magnetic Resonance Imaging (MRI)
      • Ultrasound
    • By Application
      • Cardiovascular Disease
      • Oncology
      • Gastrointestinal Disorders
      • Neurological Disorders
      • Other Indications
  • Global Diagnostic Radiopharmaceuticals and Contrast Media Market, By Geography
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East & Africa
  • Company Profiles:
    • Siemens Healthineers
    • Nordion Inc.
    • Lantheus Holdings Inc.
    • Guerbet Group
    • GE Healthcare
    • Curium
    • Bracco Imaging SpA
    • Bayer AG
    • Cardinal Health Inc.
    • NTP Radioisotopes SOC Ltd.

Table of Contents:

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Radiopharmaceuticals
    • Market Snapshot, By Contrast Media
    • Market Snapshot, By Geography
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Rise in burden of cardiovascular diseases and cancer worldwide
    • Short half-life of radiopharmaceuticals and high costs of the techniques
    • Increasing demand for image-guided procedures and diagnostics
  • Impact Analysis
  • Key Highlights
  • Regulatory Scenario
  • Product launch/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario

4. Global Diagnostic Radiopharmaceuticals and Contrast Media Market - Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Epidemiology
  • Supply Side and Demand Side Analysis
  • Economic Impact

5. Global Diagnostic Radiopharmaceuticals and Contrast Media Market, By Radiopharmaceuticals, 2017-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • By Type of Imaging Modality
    • SPECT
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
    • PET
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
  • By Application
    • Diagnostic Application
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
    • Therapeutic Application
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)

6. Global Diagnostic Radiopharmaceuticals and Contrast Media Market, By Contrast Media, 2017-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • By Procedure
    • X-Ray/Computed Tomography (CT)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
    • Magnetic Resonance Imaging (MRI)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
    • Ultrasound
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
  • By Application
    • Cardiovascular Disease
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
    • Oncology
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
    • Gastrointestinal Disorders
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
    • Neurological Disorders
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
    • Other Indications
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)

7. Global Diagnostic Radiopharmaceuticals and Contrast Media Market, By Geography, 2017-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Radiopharmaceuticals, 2017-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Contrast Media, 2017-2030,(US$ Mn)
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Radiopharmaceuticals, 2017-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Contrast Media, 2017-2030,(US$ Mn)
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Radiopharmaceuticals, 2017-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Contrast Media, 2017-2030,(US$ Mn)
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Radiopharmaceuticals, 2017-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Contrast Media, 2017-2030,(US$ Mn)
  • Middle East & Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Radiopharmaceuticals, 2017-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Contrast Media, 2017-2030,(US$ Mn)

8. Competitive Landscape

  • Siemens Healthineers
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Nordion Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Lantheus Holdings Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Guerbet Group
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • GE Healthcare
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Curium
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Bracco Imaging SpA
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Bayer AG
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • NTP Radioisotopes SOC Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Cardinal Health Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Analyst Views

9. Section

  • Research Methodology
  • About us